Brian Goff's most recent trade in Intellia Therapeutics Inc was a trade of 11,450 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | Brian Goff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 11,450 | 11,450 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Brian Goff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 8,000 | 23,409 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 142,500 | 142,500 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 39,000 | 39,000 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 18,000 | 36,000 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 18,000 | 101,139 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 8,794 | 92,345 (0%) | 0% | 35.5 | 312,539 | Common stock |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 8,500 | 87,292 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 8,500 | 8,500 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 4,153 | 83,139 (0%) | 0% | 35.5 | 147,598 | Common stock |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2024 | 22,691 | 22,691 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2024 | 22,691 | 89,883 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.75 per share. | 08 Aug 2024 | 11,091 | 78,792 (0%) | 0% | 42.7 | 474,140 | Common stock |
| Intellia Therapeutics Inc | Brian Goff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 22,297 | 22,297 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Brian Goff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 15,409 | 15,409 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2024 | 25,527 | 79,307 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2024 | 25,527 | 76,583 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 48.84 per share. | 05 Jun 2024 | 12,115 | 67,192 (0%) | 0% | 48.8 | 591,697 | Common stock |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 195,500 | 195,500 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 54,000 | 54,000 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 8,500 | 57,936 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 8,500 | 17,000 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 32.57 per share. | 01 Mar 2024 | 4,156 | 53,780 (0%) | 0% | 32.6 | 135,361 | Common stock |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 17,018 | 102,110 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 17,018 | 57,071 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 21.64 per share. | 20 Jan 2024 | 7,635 | 49,436 (0%) | 0% | 21.6 | 165,221 | Common stock |
| Agios Pharmaceuticals Inc | Goff Brian | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 25,527 | 52,119 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 25,527 | 119,128 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | Goff Brian | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 22.99 per share. | 05 Jan 2024 | 12,066 | 40,053 (0%) | 0% | 23.0 | 277,397 | Common stock |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2023 | 22,691 | 36,770 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2023 | 22,691 | 45,382 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.48 per share. | 08 Aug 2023 | 10,178 | 26,592 (0%) | 0% | 25.5 | 259,335 | Common stock |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 25,528 | 25,528 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 25,528 | 144,655 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 28.36 per share. | 28 Jun 2023 | 11,449 | 14,079 (0%) | 0% | 28.4 | 324,694 | Common stock |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 94,500 | 94,500 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 25,500 | 25,500 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Aug 2022 | 561,083 | 561,083 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Brian Goff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Aug 2022 | 68,073 | 68,073 | - | - | Restricted stock units |